Breaking News, Collaborations & Alliances

BioVaxys, Wuxi Biologics Enter Bioproduction Agreement

To synthesize proteins for SARS-CoV-2 vaccine and COVID-T immunodiagnostic programs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioVaxys Technology, a provider of haptenized protein vaccines for antiviral and cancer applications, has entered into a major bioproduction agreement with WuXi Biologics, a global contract development and manufacturing organization (CDMO) and business unit of Shanghai-based Wuxi AppTec, to produce SARS-CoV-2 s-proteins required by BioVaxys for BVX-0320, its COVID-19 vaccine candidate, and for its Covid-T immunodiagnostic program.   WuXi will synthesize high yields of fully characterized, Good L...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters